BioArctic says Rolling Sbla Initiated To U.S. FDA For Leqembi® Iqlik™ As Subcutaneous Starting Dose For Early Alzheimer's Disease Treatment Under Fast Track Status
Sept 2 (Reuters) - BioArctic AB BIOAb.ST:
ROLLING SBLA INITIATED TO THE U.S. FDA FOR LEQEMBI® IQLIK™ (LECANEMAB-IRMB) AS A SUBCUTANEOUS STARTING DOSE FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE UNDER FAST TRACK STATUS
Further company coverage: [BIOAb.ST]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Intel Foundry Gains ‘High-Profile’ Customer, Tesla Becomes First Major Customer for 14A Technology

Anthropic Eclipses OpenAI in Secondary Market as Valuation Hits $1 Trillion Milestone, Is the AI Market Overheating Now?

Robinhood Stock Predictions: Can HOOD Reach the $1,000 Milestone?

Tesla Officially Announces. Third-Generation Humanoid Robot to Debut Mid-Year, Mass Production to Start in Third Quarter

Intel Better-Than-Expected Earnings Released, Stock Surges 20% After-Hours, AI Computing Power Enters CPU Moment?

Tradingkey








